Journal article

NAB2 is a novel immune stimulator of MDA-5 that promotes a strong type I interferon response

  • Oberson, Anne Pharmacology, Department of Medicine, Faculty of Science, University of Fribourg, Switzerland
  • Spagnuolo, Lorenzo Pharmacology, Department of Medicine, Faculty of Science, University of Fribourg, Switzerland - School of Pharmaceutical Sciences, University of Geneva, Switzerland - Department of Anesthesiology, Pharmacology and Intensive Care, Faculty of Medicine, University of Geneva, Switzerland
  • Puddinu, Viola School of Pharmaceutical Sciences, University of Geneva, Switzerland - Department of Anesthesiology, Pharmacology and Intensive Care, Faculty of Medicine, University of Geneva, Switzerland
  • Barchet, Winfried German Center for Infection Research, Cologne-Bonn, Germany - Institute for Clinical Chemistry and Clinical Pharmacology, University of Bonn, Germany
  • Rittner, Karola Transgene S.A., Parc d?Innovation, Illkirch-Graffenstaden, France
  • Bourquin, Carole Pharmacology, Department of Medicine, Faculty of Science, University of Fribourg, Switzerland - School of Pharmaceutical Sciences, University of Geneva, Switzerland - Department of Anesthesiology, Pharmacology and Intensive Care, Faculty of Medicine, University of Geneva, Switzerland
Show more…
    19.01.2018
Published in:
  • Oncotarget. - 2018, vol. 9, no. 5
English Novel adjuvants are needed to increase the efficacy of vaccine formulations and immune therapies for cancer and chronic infections. In particular, adjuvants that promote a strong type I IFN response are required, since this cytokine is crucial for the development of efficient anti-tumoral and anti-viral immunity. Nucleic acid band 2 (NAB2) is a double- stranded RNA molecule isolated from yeast and identified as an agonist of the pattern- recognition receptors TLR3 and MDA-5. We compared the ability of NAB2 to activate innate immunity with that of poly(I:C), a well-characterized TLR3 and MDA-5 agonist known for the induction of type I IFN. NAB2 promoted stronger IFN-α production and induced a higher activation state of both murine and human innate immune cells compared to poly(I:C). This correlated with a stronger activation of the signalling pathway downstream of MDA-5, and IFN-α induction was dependent on MDA-5. Upon injection, NAB2 induced higher levels of serum IFN-α in mice than poly(I:C). These results suggest that NAB2 has the potential to become an efficient adjuvant for the induction of type-I IFN responses in therapeutic immunization against cancer or infections.
Faculty
Faculté des sciences et de médecine
Department
Département de Médecine
Language
  • English
Classification
Biology
License
License undefined
Identifiers
Persistent URL
https://folia.unifr.ch/unifr/documents/306653
Statistics

Document views: 4 File downloads:
  • bou_nna.pdf: 1